Yes We Can! We Can Abolish the NCCAM! Part III

How We Got Here: From Alternative to Integrative

The story starts with political enthusiasm, not a triumphant scientific breakthrough. The Office of Alternative Medicine was formally established in the early 1990s, and by 1998 Congress had elevated it into NCCAM. That alone told you a lot. This was not a center built because mainstream biomedicine had discovered a mountain of neglected evidence. It was built because public interest, advocacy, and politics created momentum.

To be fair, public interest was real. Americans were, and still are, spending serious money on complementary health approaches. Surveys over the years have shown widespread use of supplements, chiropractic care, yoga, meditation, and acupuncture. Back pain, stress, and musculoskeletal complaints are among the most common reasons people reach for these options. Anyone acting like this trend never happened is arguing with reality and losing badly.

But popularity is not proof. Astrology is popular too, and that does not mean NASA needs a moon base for Mercury retrograde.

Over time, the old “alternative medicine” label became harder to defend. It sounded too oppositional, too detached from modern standards, and frankly too easy to ridicule. So the language shifted. “Alternative” became “complementary.” Then “integrative.” The rebrand was not random. It reflected a real tension: some non-drug approaches can help some patients under some conditions, but many classic CAM claims still collapse under proper testing. The new language was an attempt to keep the parts with plausible value while backing away from the parts that smelled like 19th-century brochure copy.

The Core Argument for Abolishing NCCAM

1. A Separate Center Can Legitimize Weak Ideas

The strongest criticism of NCCAM was never that research on nontraditional therapies should never happen. It was that a dedicated center can grant institutional prestige to ideas that have not earned it. Once the federal government creates a named center, the public hears something simple and seductive: “This must be a serious field.”

That becomes a problem when the field includes treatments with wildly different levels of plausibility. Mindfulness for chronic stress is not the same thing as homeopathy. Yoga for flexibility is not the same thing as energy healing. Studying diet or pain coping strategies is not the same thing as studying whether invisible life force fields can be rearranged by someone waving near your shoulders like they are tuning an old television.

Put all of it under one umbrella and the fringe borrows credibility from the reasonable. That is the branding trick. It is also the policy trap.

2. Public Money Should Follow Scientific Probability

NIH research dollars are limited. Every grant has an opportunity cost. If money goes toward testing claims with weak biological plausibility and a long history of failure, that money is not going toward cancer biology, infection control, maternal health, or interventions that might actually change clinical practice.

Critics of NCCAM made this point for years: human trials should not become expensive scavenger hunts for therapies that lack a convincing scientific basis. That is not closed-mindedness. That is triage. Research is supposed to be curious, not gullible.

Some of the center’s most infamous controversies came from funding lines of inquiry that critics argued should never have advanced so far in the first place. The complaint was not “science found no benefit.” Science often finds no benefit. The complaint was “why were we here at all?” That distinction matters.

3. Evidence-Based Pieces Can Live Elsewhere

If an intervention is biologically plausible and clinically important, it does not need a special sanctuary. It can be studied by the most relevant NIH institute, an Office of Dietary Supplements program, an NCI cancer supportive care initiative, or broader pain and rehabilitation research networks. In fact, moving serious questions into ordinary evidence standards is the whole point.

That is why the best argument for abolishing NCCAM was never “stop studying everything people call complementary.” It was “stop treating this mixed bag as a protected category.” Keep the good science. Retire the bureaucratic halo.

The Fair Counterargument: Some Complementary Approaches Actually Help

If this were merely a tale of pseudoscience versus common sense, the debate would be easy and much shorter. But reality is more annoying than that. Some approaches once parked in the CAM lot now have evidence for limited uses, especially in chronic pain and symptom management.

Clinical guidance over the last decade has increasingly favored some non-drug options before escalating to riskier medication pathways. For chronic low-back pain, for example, evidence-based guidance has included therapies such as exercise, acupuncture, mindfulness-based stress reduction, tai chi, yoga, and spinal manipulation as options worth considering. That does not mean they are miracle cures. It means they may offer modest benefits for some patients, often with lower risk than long-term opioid-heavy treatment strategies.

This is where the conversation gets more mature. The right question is not “Is it alternative?” The right question is “What is the quality of the evidence, what is the size of the benefit, what are the risks, and for whom does it work?”

That is also why today’s NCCIH prefers the language of “complementary” and “integrative” health. The center’s current framing emphasizes rigorous investigation and generally rejects the idea that these approaches should replace conventional care. In plain English: if something works, it should join the team, not start a cult in the parking lot.

Where the Old Critics Were Right

Even after the rebrand, the old criticism still lands with surprising force. A separate center devoted to this territory invites mission drift. Once a bureaucracy exists, it naturally seeks programs, partnerships, strategic plans, and a reason to keep the lights on. A center does not usually write a yearly memo that says, “Good news, we tested the weak stuff and should now dissolve ourselves.” Bureaucracies are many things. Terminally self-aware is not one of them.

Critics also warned that language can blur standards. “Whole person health,” “patient-centered care,” and “nonpharmacologic support” can all describe legitimate goals. But they can also function as soft-focus marketing if they are not tied to measurable outcomes and high-quality trials. Warm words are not data. A soothing website is not a dose-response curve.

Then there is the supplement problem. Under the U.S. supplement framework, FDA does not approve dietary supplements for safety and effectiveness before they are marketed the way it does for drugs. That leaves consumers navigating a noisy marketplace filled with products that sound medical, look medical, and are marketed with the confidence of a man selling miracle windshield wipers at a gas station. A research center can help study such products, but it can also unintentionally feed the public impression that the marketplace has already been vetted more thoroughly than it has.

What an Evidence-First Alternative Would Look Like

Merge the science, not the mythology

If the goal is better care, the smartest reform is not to ban investigation. It is to mainstream the investigation. Nutritional supplement research belongs with supplement science and pharmacology. Behavioral pain interventions belong with pain medicine, rehabilitation, psychiatry, and primary care. Manual therapies belong where musculoskeletal outcomes are studied seriously. Cancer symptom relief belongs with oncology supportive care.

Use the same rules for everyone

No therapy should get easier evidence thresholds just because it is old, natural, spiritual, trendy, or wrapped in bamboo-colored branding. The test remains the same: plausibility, mechanism, trial quality, reproducibility, effect size, safety, and clinical usefulness. If a therapy cannot survive those standards, it does not deserve a federal life raft made of euphemisms.

Stop rewarding category-based thinking

The category “CAM” has always been unstable. Once a treatment is proven effective, it tends to stop being alternative and just becomes medicine. That means the category is partly defined by what has not yet made the cut. Building a permanent institution around that category is like founding a Department of Maybe.

So, Should We Abolish It?

If the question is whether the old NCCAM model deserved retirement, the answer is yes. A separate center built around “alternative” medicine was always structurally awkward. It mixed plausible non-drug care with implausible claims, encouraged confusion between public interest and scientific merit, and risked lending federal legitimacy to weak ideas.

If the question is whether the useful research should disappear, the answer is no. Pain management, stress reduction, exercise-based support, symptom relief, sleep improvement, and careful supplement science all deserve continued investigation. They just do not need a bureaucratic island defined by a category that medicine itself keeps outgrowing.

So the real reform position is simpler than the slogans. Abolish the special pleading. Abolish the prestige shield for low-plausibility claims. Abolish the category as a protected kingdom. Keep the science. Move it where it belongs. Test it like everything else. Let evidence do the hiring and firing.

That is the grown-up version of “Yes we can.” Less chant, more method.

Experiences From the Real World: Why This Debate Never Feels Abstract

The reason people keep returning to the NCCAM debate is that it never stays in the policy basement for long. It shows up in exam rooms, pharmacy aisles, family group chats, wellness podcasts, and late-night searches that begin with “nothing else has worked.” For patients, this is rarely an ideological journey. It is usually a practical one. A person with chronic back pain tries physical therapy, gets partial relief, adds yoga, then asks about acupuncture because a neighbor swears by it. Another person undergoing cancer treatment looks for massage, ginger, meditation, or breathing exercises to manage nausea, pain, fear, and exhaustion. These experiences are real, and they deserve respect.

But there is another side to those experiences. Primary care doctors, oncologists, pharmacists, and nurses routinely meet patients who assume that “natural” means safe, that supplements are FDA-approved before sale, or that a product described as supporting “immune balance” must have been proven to do something measurable. That is where confusion becomes costly. A patient delays evidence-based treatment because an online personality promised a detox plan. Someone spends hundreds of dollars on powders and capsules that offer no clear benefit. A family member mistakes government-funded research for government endorsement and says, “If NIH studied it, it must work.”

Researchers live in that awkward middle too. Many scientists who care about symptom relief, pain reduction, and behavior-based treatment do not want their work grouped with implausible claims. They want strong trial design, clear outcomes, realistic mechanisms, and honest interpretation. They know some non-drug approaches may help, but they also know that vague language can turn modest findings into marketing fireworks. One positive study on short-term pain scores becomes “ancient healing finally validated,” which is how nuance gets flattened into clickbait.

Taxpayers experience this debate differently. They may not read grant abstracts, but they understand the basic fairness question: should public money test every popular claim, or should it focus on the most promising paths first? Most people are not against curiosity. They are against waste dressed in a lab coat. They do not mind research on stress, sleep, pain, or symptom management. They mind the feeling that scientific standards get softer whenever a therapy arrives wearing the words “holistic” and “integrative.”

What ties all of these experiences together is not cynicism. It is the need for trustworthy sorting. Patients need help identifying what is low-risk and potentially useful, what is unproven, and what is simply bad medicine with a softer font. Clinicians need institutions that clarify rather than blur. Researchers need funding structures that reward rigor instead of category loyalty. And the public needs a health system willing to say two things at once: people’s suffering is real, and not every appealing answer deserves scientific promotion. That is why the fight over NCCAM, old name or new name, still feels personal. It is really a fight over who gets to define credible care when hope is expensive and certainty is scarce.